Biotech Daily Monday July 11, 2016 JUNIPER PRODUCES PHARMAUST...

Biotech Daily
Monday July 11, 2016

JUNIPER PRODUCES PHARMAUST MONEPANTEL (PPL-1) FOR TRIALS

Pharmaust says that Juniper Pharma Services has completed the manufacture of 1,000
capsules of monepantel, formerly PPL-1, for its cancer programs.
Pharmaust said that the Nottingham, England-based Juniper capsules would be provided
to the University of Cambridge for its dog cancer trial (BD: Jun 27, 2016).
The company said that 20,000 capsules would be produced to support the clinical work
and would enable dog owners to administer the drug without the palatability challenges in
the previous Sydney trial in 2014 and 2015.
Pharmaust said that Juniper would retain capsules for on-going stability trials to determine
whether there was any deterioration of the product over time.
Pharmaust said that both the human and dog trials would determine the effects of
monepantel on tumor growth as determined by measurement of the size of tumors and
whether progression was slowed.
Pharmaust was up 0.3 cents or 3.5 percent to 8.8 cents.